Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Prostate Cancer Patient Perspectives on the Use of Information in Treatment Decision-Making: A Systematic Review and Qualitative Meta-synthesis.

Kandasamy S, Khalid AF, Majid U, Vanstone M.

Ont Health Technol Assess Ser. 2017 May 1;17(7):1-32. eCollection 2017.

2.

Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.

Health Quality Ontario .

Ont Health Technol Assess Ser. 2017 May 1;17(6):1-75. eCollection 2017.

3.
4.

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Fleshner K, Carlsson SV, Roobol MJ.

Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Review.

5.

Utility of Prostate Cancer Screening in Kidney Transplant Candidates.

Vitiello GA, Sayed BA, Wardenburg M, Perez SD, Keith CG, Canter DJ, Ogan K, Pearson TC, Turgeon N.

J Am Soc Nephrol. 2016 Jul;27(7):2157-63. doi: 10.1681/ASN.2014121182. Epub 2015 Dec 23.

6.

Knowledge and attitude of the population toward cancer prostate Riyadh, Saudi Arabia.

Arafa MA, Farhat KH, Rabah DM.

Urol Ann. 2015 Apr-Jun;7(2):154-8. doi: 10.4103/0974-7796.150516.

7.

Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013".

Combs SE, Debus J, Feick G, Hadaschik B, Hohenfellner M, Schüle R, Zacharias JP, Schwardt M.

Radiat Oncol. 2014 Nov 4;9:224. doi: 10.1186/s13014-014-0224-4.

8.

Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives.

Gwede CK, Davis SN, Wilson S, Patel M, Vadaparampil ST, Meade CD, Rivers BM, Yu D, Torres-Roca J, Heysek R, Spiess PE, Pow-Sang J, Jacobsen P.

Am J Health Promot. 2015 Jul-Aug;29(6):393-401. doi: 10.4278/ajhp.130904-QUAL-463. Epub 2014 Jun 26.

9.

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Hill EM, Davies C, Ng SY, Neal DE, Hamdy FC, Martin RM; CAP trial group.

Br J Cancer. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. Epub 2014 May 27.

10.

A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer.

Patel N, Vogel R, Chandra-Kuntal K, Glasgow W, Kelavkar U.

PLoS One. 2014 Mar 6;9(3):e88841. doi: 10.1371/journal.pone.0088841. eCollection 2014.

11.

Transperineal ultrasound-guided 12-core prostate biopsy: an extended approach to diagnose transition zone prostate tumors.

Yao MH, Zou LL, Wu R, Guo LH, Xu G, Xie J, Li P, Wang S.

PLoS One. 2014 Feb 25;9(2):e89171. doi: 10.1371/journal.pone.0089171. eCollection 2014.

12.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

13.

Perceptions of prostate cancer fatalism and screening behavior between United States-born and Caribbean-born Black males.

Cobran EK, Wutoh AK, Lee E, Odedina FT, Ragin C, Aiken W, Godley PA.

J Immigr Minor Health. 2014 Jun;16(3):394-400. doi: 10.1007/s10903-013-9825-5.

14.

Se rapprocher avec les survivants de la cancer de la prostate.

Siemens DR.

Can Urol Assoc J. 2012 Oct;6(5):351. doi: 10.5489/cuaj.12269. No abstract available.

15.

Connecting with prostate cancer survivors.

Siemens DR.

Can Urol Assoc J. 2012 Oct;6(5):349. doi: 10.5489/cuaj.12268. No abstract available.

16.

First, do no harm.

Pimlott N.

Can Fam Physician. 2012 Sep;58(9):915. No abstract available.

17.

Evaluating genetic risk for prostate cancer among Japanese and Latinos.

Cheng I, Chen GK, Nakagawa H, He J, Wan P, Laurie CC, Shen J, Sheng X, Pooler LC, Crenshaw AT, Mirel DB, Takahashi A, Kubo M, Nakamura Y, Al Olama AA, Benlloch S, Donovan JL, Guy M, Hamdy FC, Kote-Jarai Z, Neal DE, Wilkens LR, Monroe KR, Stram DO, Muir K, Eeles RA, Easton DF, Kolonel LN, Henderson BE, Le Marchand L, Haiman CA.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2048-58. doi: 10.1158/1055-9965.EPI-12-0598. Epub 2012 Aug 24.

18.

The search for diagnostic markers in sepsis: many miles yet to go.

Calfee CS, Pugin J.

Am J Respir Crit Care Med. 2012 Jul 1;186(1):2-4. doi: 10.1164/rccm.201205-0854ED. No abstract available.

19.

The confusion surrounding prostate cancer screening faced by family physicians.

Hoag NA, So AI.

Can Urol Assoc J. 2012 Jun;6(3):194-5. doi: 10.5489/cuaj.12123. No abstract available.

Supplemental Content

Support Center